AX-2026-042085

MOTS-c · 10 mg declared · Shenzhen Hybio Pharmaceutical Co., Ltd. · lot HYB-2606-D7858

PASSVERIFIED

Report ID: AX-2026-042085
Compound: MOTS-c
Compound class: Metabolic and mitochondrial peptides
Supplier: HYB — Shenzhen Hybio Pharmaceutical Co., Ltd.
Batch / lot: HYB-2606-D7858
Declared label claim: 10mg
Laboratory: Janoshik Analytical
Assay date: 10 Aug 2026
Submitted: 03 Sep 2026
Quarter: 2026-Q3
Submitter: a.girard
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the metabolic and mitochondrial peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.51	% area	≥ 98.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.49	% area	≤ 2.0	PASS
Largest single impurity	RP-HPLC — bis-sulfoxide (+32 Da)	0.29	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	2173.0918	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	2173.0896	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-1.0	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	2.31	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.35	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.72	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	2.05	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.59	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	10.33	min	10.42 ± 0.30 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.01	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	57,337	—	≥ 20,000	PASS
Resolution to nearest impurity	vs des-Met1 (−131 Da)	1.24	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 57,337, and skew follows the reported asymmetry factor of 1.01. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.29 % impurity against a 99.51 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	MOTS-c — main peak	10.33	4,836,494	99.51	—
2	bis-sulfoxide (+32 Da)	9.67	14,095	0.29	+31.990
3	deamidated (+1 Da)	10.03	6,318	0.13	+0.984
4	Met1 sulfoxide (+16 Da)	9.95	2,430	0.05	+15.995
5	des-Met1 (−131 Da)	10.55	972	0.02	-131.040
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 2173.0918 Da, computed from C101H152N28O22S2. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 2173.0896 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
4+	544.2802	544.2797	-0.0005	8.6
3+	725.3712	725.3705	-0.0007	57.0
2+	1087.5532	1087.5521	-0.0011	100.0
1+	2174.0991	2174.0969	-0.0022	52.3

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.35	99.51	divergence -0.19 pp vs batch median
Total impurities (% area)	0.65	0.49
Largest single impurity (% area)	0.48	0.29
Water (%)	not stated	2.31
Counter-ion (%)	not stated	4.35
Peptide content (%w/w)	91.7	not determined
Endotoxin (EU/mg)	1.59	2.05
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 27 d) → laboratory (courier, cold pack, 9 d) → assay.
Assay date: 10 Aug 2026
Submitted to the index: 03 Sep 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

wide_iqr03 Sep 2026

A single result at 99.51 % is one draw. What makes a supplier's process legible is the spread across its lots, and that is on the scorecard rather than here. This record is one good point in a distribution worth reading whole.

cleavage_cocktail03 Sep 2026

Alkylation artefacts from a scavenger-poor cleavage would appear as a +58 or +76 family here. Absent, which says the cleavage was run properly.

Section 7

Related records

Same batch — lot HYB-2606-D7858 n=11

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042080	HYB-2606-D7858	VendorInvestigate	2026-Q3	98.29	2.10	95.6	Laboratory-retained	0	PASS
AX-2026-042081	HYB-2606-D7858	Nordanalyt	2026-Q3	99.68	3.31	96.5	Laboratory-retained	0	PASS
AX-2026-042082	HYB-2606-D7858	Janoshik	2026-Q3	99.86	2.13	—	Buyer-sourced	0	PASS
AX-2026-042083	HYB-2606-D7858	Medutest	2026-Q3	99.93	2.02	—	Buyer-sourced	0	PASS
AX-2026-042084	HYB-2606-D7858	Janoshik	2026-Q3	99.28	2.79	107.3	Buyer-sourced	0	PASS
AX-2026-042086	HYB-2606-D7858	Janoshik	2026-Q3	99.93	3.02	—	Buyer-sourced	1	MARGINAL
AX-2026-042087	HYB-2606-D7858	Janoshik	2026-Q3	99.54	3.05	—	Buyer-sourced	0	PASS
AX-2026-042088	HYB-2606-D7858	PeptideMeter	2026-Q3	99.22	2.21	—	Buyer-sourced	0	PASS
AX-2026-042089	HYB-2606-D7858	Medutest	2026-Q3	99.38	2.65	—	Buyer-sourced	0	PASS
AX-2026-042090	HYB-2606-D7858	Janoshik	2026-Q3	99.57	2.36	—	Buyer-sourced	1	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent MOTS-c records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042083	HYB	HYB-2606-D7858	Medutest	2026-Q3	99.93	2.02	—	Buyer-sourced	0	PASS
AX-2026-042090	HYB	HYB-2606-D7858	Janoshik	2026-Q3	99.57	2.36	—	Buyer-sourced	1	FAIL
AX-2026-042084	HYB	HYB-2606-D7858	Janoshik	2026-Q3	99.28	2.79	107.3	Buyer-sourced	0	PASS
AX-2026-042087	HYB	HYB-2606-D7858	Janoshik	2026-Q3	99.54	3.05	—	Buyer-sourced	0	PASS
AX-2026-042088	HYB	HYB-2606-D7858	PeptideMeter	2026-Q3	99.22	2.21	—	Buyer-sourced	0	PASS
AX-2026-042086	HYB	HYB-2606-D7858	Janoshik	2026-Q3	99.93	3.02	—	Buyer-sourced	1	MARGINAL
AX-2026-042081	HYB	HYB-2606-D7858	Nordanalyt	2026-Q3	99.68	3.31	96.5	Laboratory-retained	0	PASS
AX-2026-042089	HYB	HYB-2606-D7858	Medutest	2026-Q3	99.38	2.65	—	Buyer-sourced	0	PASS

Other recent HYB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042083	MOTS-c	HYB-2606-D7858	Medutest	2026-Q3	99.93	2.02	—	Buyer-sourced	0	PASS
AX-2026-042090	MOTS-c	HYB-2606-D7858	Janoshik	2026-Q3	99.57	2.36	—	Buyer-sourced	1	FAIL
AX-2026-042084	MOTS-c	HYB-2606-D7858	Janoshik	2026-Q3	99.28	2.79	107.3	Buyer-sourced	0	PASS
AX-2026-042087	MOTS-c	HYB-2606-D7858	Janoshik	2026-Q3	99.54	3.05	—	Buyer-sourced	0	PASS
AX-2026-042088	MOTS-c	HYB-2606-D7858	PeptideMeter	2026-Q3	99.22	2.21	—	Buyer-sourced	0	PASS
AX-2026-042086	MOTS-c	HYB-2606-D7858	Janoshik	2026-Q3	99.93	3.02	—	Buyer-sourced	1	MARGINAL
AX-2026-042091	CJC-1295 with DAC	HYB-2608-E7391	Janoshik	2026-Q3	99.38	5.53	—	Buyer-sourced	0	PASS
AX-2026-042081	MOTS-c	HYB-2606-D7858	Nordanalyt	2026-Q3	99.68	3.31	96.5	Laboratory-retained	0	PASS